Samchundang Pharm Surrenders "Emperor Stock" Status, Fails to Bridge Gap Between Expectations and Reality
Many Partners Remain Undisclosed, Wide Gap Between Disclosed and Announced Contract Values
R&D Spending Down 25%, Only 35 Research Staff
Contrasts With Series of Clinical Trials and Contracts
Received Lowest ESG Rating for Three Consecutive
Samchundang Pharm, which jumped to the top of the KOSDAQ market capitalization rankings and drew attention as a so-called "emperor stock," plummeted in a single day. On March 31, Samchundang Pharm's stock price closed at 829,000 won, down a staggering 29.98% from the previous day. The surge in expectations driven by the submission of a clinical trial protocol for oral insulin and a series of global semaglutide generic contracts evaporated in an instant. The market is divided on whether this is simply the volatile fluctuation characteristic of biotech stocks or a temporary pause.
According to the bio industry and investment market on April 1, 61% of Samchundang Pharm's sales, a company founded in 1943, come from ophthalmic products. The company's transformation began in 2014 when it developed the Eylea biosimilar "SCD411 (Vizenfree)." After more than a decade of effort, the company secured product approvals in Korea, Canada, Europe, and Japan. According to the company, after its launch in Canada last year, it achieved 9.7 billion won in sales for that product alone within three months.
Since the beginning of this year, Samchundang Pharm has consecutively announced favorable contract news. In January, the company announced a joint development and commercialization partnership contract for oral semaglutide for the Japanese market. In February, it disclosed exclusive license and commercialization contracts for generic versions of the oral diabetes drug Rybelsus and the oral obesity drug Wegovy (oral semaglutide) in 11 European countries including the United Kingdom. On March 30, the company announced that it had signed a U.S. license agreement for the Rybelsus generic and Wegovy oral generic. The market responded particularly strongly to Samchundang Pharm’s application for approval of Phase 1 and 2 clinical trial plans for oral insulin in Europe. The prospect that oral insulin, if realized, could become a game changer by completely shifting the current treatment paradigm contributed to this reaction.
However, skepticism remains in the market regarding the substance and feasibility of these contracts. Unlike major biotech firms such as Alteogen, Ligachem Bio, and ABL Bio, Samchundang Pharm has often not disclosed its license contract partners. It is customary for major biotechs with innovative drugs or platform technologies to reveal their global big pharma partners when signing licensing deals, as the partner's solid market position itself serves as a guarantee of trust. This is why some point out that information regarding Samchundang Pharm’s contracts does not fully deliver value as investment information.
The gap in contract amounts is also notable. For the European contracts, the company announced through a press release that the total contract size was approximately 5.3 trillion won, but the down payment and milestone payments specified in the regulatory filing amount to only about 50.8 billion won. The company stated on its website that "the contract clearly specifies the annual sales volume, price, and total sales for the 10-year contract period." However, in the pharmaceutical and biotech industry, the size of license contracts is usually based on the sum of the down payment and milestones, with royalties after commercialization counted separately. By this standard, the announced amount and the disclosed amount differ by more than a factor of 100.
Doubts also arise regarding the contract structure. Both the U.S. and Japanese contracts are structured so that the partner companies bear little risk. In the case of the U.S. contract, the partner can terminate the agreement with just 90 days’ notice if commercialization becomes commercially or scientifically unfeasible. For the Japanese contract, if the results of the bioequivalence (BE) study or approval by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) become unachievable, the partner can terminate within 18 months. All three contract disclosures for Japan, Europe, and the United States specify the caveat that "revenue recognition is conditional and realization may not be possible." This means that a signed contract does not guarantee revenue.
Questions have also been raised about whether Samchundang Pharm’s fundamentals can support a market capitalization in the tens of trillions of won. The company’s consolidated sales last year were 231.8 billion won, with operating profit at 8.5 billion won. If clinical trials fail or commercialization is delayed, these figures are considered insufficient to support the current stock price. Research and development spending was also 15.6 billion won last year, a 25% decrease from the previous year’s 20.8 billion won, which contrasts with the flurry of oral insulin clinical trial applications and global semaglutide generic contracts this year. The company has only 35 research staff members.
Samchundang Pharm has received the lowest D grade for three consecutive years from the Korea ESG Standards Institute, indicating failure in internal controls and accounting transparency. On the previous day, the Korea Exchange announced its intent to designate Samchundang Pharm as an unfaithful disclosure company, citing the company’s failure to properly fulfill reporting obligations after only issuing a press release on February 6 regarding business performance. The final designation will be decided by April 23.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
On March 24, CEO Jeon Inseok disclosed that he would dispose of 265,700 shares of his common stock holdings (worth approximately 250 billion won) through after-hours block trading. Although this was explained as being for gift tax payment purposes, concerns about an overhang have been raised in the market. Despite being the top stock by market capitalization on KOSDAQ, it is difficult to find analyst reports on the company. Over the past year, Korea Investment & Securities was the only brokerage to publish a report, and no target price was provided.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.